HALOZYME THERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost
HALOZYME THERAPEUTICS, INC. (HALO) had Debt Securities, Available-for-sale, Amortized Cost of $179.24 million as of 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2023-05-09
- 2023-03-31: Debt Securities, Available-for-sale, Amortized Cost $179.24M.
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost $129.54M.
- 2022-09-30: Debt Securities, Available-for-sale, Amortized Cost $120.28M.
- 2022-06-30: Debt Securities, Available-for-sale, Amortized Cost $120.46M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2023-03-31 | $179.24M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $129.54M 10-Q · filed 2023-05-09 |
| 2022-09-30 | $120.28M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $120.46M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $671.07M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $622.82M 10-K · filed 2023-02-21 |
| 2021-09-30 | $324.22M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $308.34M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $264.85M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $220.22M 10-K · filed 2022-02-22 |
| 2020-09-30 | $280.51M 10-Q · filed 2020-11-02 |
| 2020-06-30 | $250.74M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $263.34M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $300.83M 10-Q · filed 2020-11-02 |
| 2019-09-30 | $178.38M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $220.01M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $268.04M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $296.84M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |